questionsmedicales.fr
Composés polycycliques
Hydrocarbures aromatiques polycycliques
Benzocycloheptènes
Benzocycloheptènes : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Spectroscopie
Chromatographie
Tests de toxicité
Efficacité
Analyse sanguine
Échantillons biologiques
Marqueurs biologiques
Exposition
Imagerie moléculaire
Distribution tissulaire
Symptômes
5
Effets secondaires
Réactions allergiques
Symptômes neurologiques
Troubles de la coordination
Éruptions cutanées
Réaction allergique
Système respiratoire
Irritations
Prévention
5
Équipements de protection
Protocoles de sécurité
Milieu industriel
Exposition
Réglementations
Usage industriel
Évaluation des risques
Environnements de travail
Traitements
5
Intoxication
Soins symptomatiques
Antidotes
Composés chimiques
Antihistaminiques
Réactions allergiques
Hospitalisation
Symptômes graves
Suivi médical
Effets à long terme
Complications
5
Complications
Lésions organiques
Cancers
Potentiel cancérigène
Effets sur la reproduction
Études animales
Allergies
Sensibilisations
Système immunitaire
Infections
Facteurs de risque
5
Travailleurs
Industrie chimique
Prédispositions génétiques
Sensibilité aux toxines
Antécédents médicaux
Allergies
Environnement de travail
Ventilation
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Benzocycloheptènes : Questions médicales les plus fréquentes",
"headline": "Benzocycloheptènes : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Benzocycloheptènes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-11",
"dateModified": "2025-03-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Benzocycloheptènes"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hydrocarbures aromatiques polycycliques",
"url": "https://questionsmedicales.fr/mesh/D011084",
"about": {
"@type": "MedicalCondition",
"name": "Hydrocarbures aromatiques polycycliques",
"code": {
"@type": "MedicalCode",
"code": "D011084",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Dibenzocycloheptènes",
"alternateName": "Dibenzocycloheptenes",
"url": "https://questionsmedicales.fr/mesh/D003986",
"about": {
"@type": "MedicalCondition",
"name": "Dibenzocycloheptènes",
"code": {
"@type": "MedicalCode",
"code": "D003986",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Amitriptyline",
"alternateName": "Amitriptyline",
"url": "https://questionsmedicales.fr/mesh/D000639",
"about": {
"@type": "MedicalCondition",
"name": "Amitriptyline",
"code": {
"@type": "MedicalCode",
"code": "D000639",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Butaclamol",
"alternateName": "Butaclamol",
"url": "https://questionsmedicales.fr/mesh/D002069",
"about": {
"@type": "MedicalCondition",
"name": "Butaclamol",
"code": {
"@type": "MedicalCode",
"code": "D002069",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.230"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cyproheptadine",
"alternateName": "Cyproheptadine",
"url": "https://questionsmedicales.fr/mesh/D003533",
"about": {
"@type": "MedicalCondition",
"name": "Cyproheptadine",
"code": {
"@type": "MedicalCode",
"code": "D003533",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.340"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Loratadine",
"alternateName": "Loratadine",
"url": "https://questionsmedicales.fr/mesh/D017336",
"about": {
"@type": "MedicalCondition",
"name": "Loratadine",
"code": {
"@type": "MedicalCode",
"code": "D017336",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.340.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Loratadine",
"alternateName": "Loratadine",
"url": "https://questionsmedicales.fr/mesh/D017336",
"about": {
"@type": "MedicalCondition",
"name": "Loratadine",
"code": {
"@type": "MedicalCode",
"code": "D017336",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.340.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Maléate de dizocilpine",
"alternateName": "Dizocilpine Maleate",
"url": "https://questionsmedicales.fr/mesh/D016291",
"about": {
"@type": "MedicalCondition",
"name": "Maléate de dizocilpine",
"code": {
"@type": "MedicalCode",
"code": "D016291",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.380"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nortriptyline",
"alternateName": "Nortriptyline",
"url": "https://questionsmedicales.fr/mesh/D009661",
"about": {
"@type": "MedicalCondition",
"name": "Nortriptyline",
"code": {
"@type": "MedicalCode",
"code": "D009661",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.535"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protriptyline",
"alternateName": "Protriptyline",
"url": "https://questionsmedicales.fr/mesh/D011530",
"about": {
"@type": "MedicalCondition",
"name": "Protriptyline",
"code": {
"@type": "MedicalCode",
"code": "D011530",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.650"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Benzocycloheptènes",
"alternateName": "Benzocycloheptenes",
"code": {
"@type": "MedicalCode",
"code": "D001567",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jiatian Li",
"url": "https://questionsmedicales.fr/author/Jiatian%20Li",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
},
{
"@type": "Person",
"name": "Xiangwen Tan",
"url": "https://questionsmedicales.fr/author/Xiangwen%20Tan",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
},
{
"@type": "Person",
"name": "Huanfeng Jiang",
"url": "https://questionsmedicales.fr/author/Huanfeng%20Jiang",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
},
{
"@type": "Person",
"name": "Wanqing Wu",
"url": "https://questionsmedicales.fr/author/Wanqing%20Wu",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The Effect of Effervescent and Buffered Alendronate Compared to Conventional Alendronate on Markers of Bone Turnover: A Randomized Non-inferiority Trial.",
"datePublished": "2023-10-06",
"url": "https://questionsmedicales.fr/article/37803182",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00223-023-01140-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Airway consequences of alendronic acid aspiration.",
"datePublished": "2024-08-21",
"url": "https://questionsmedicales.fr/article/39174042",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bcr-2024-260930"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effect of alendronate sodium plus vitamin D",
"datePublished": "2022-06-17",
"url": "https://questionsmedicales.fr/article/35715774",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12891-022-05521-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Orbital myositis induced by alendronate: A case report.",
"datePublished": "2023-03-17",
"url": "https://questionsmedicales.fr/article/36880870",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ene.15772"
}
},
{
"@type": "ScholarlyArticle",
"name": "Vascular response to stress: Protective action of the bisphosphonate alendronate.",
"datePublished": "2022-07-25",
"url": "https://questionsmedicales.fr/article/35879908",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/1358863X221112168"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011083"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hydrocarbures aromatiques polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011084"
},
{
"@type": "ListItem",
"position": 4,
"name": "Benzocycloheptènes",
"item": "https://questionsmedicales.fr/mesh/D001567"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Benzocycloheptènes - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Benzocycloheptènes",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Benzocycloheptènes",
"description": "Comment identifier les benzocycloheptènes ?\nQuels tests sont utilisés pour les benzocycloheptènes ?\nLes benzocycloheptènes sont-ils détectables dans le sang ?\nY a-t-il des marqueurs spécifiques pour ces composés ?\nPeut-on utiliser l'imagerie pour les benzocycloheptènes ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Alendronate#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Benzocycloheptènes",
"description": "Quels sont les effets secondaires des benzocycloheptènes ?\nLes benzocycloheptènes causent-ils des douleurs ?\nY a-t-il des symptômes neurologiques associés ?\nPeut-on observer des symptômes cutanés ?\nLes benzocycloheptènes affectent-ils le système respiratoire ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Alendronate#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Benzocycloheptènes",
"description": "Comment prévenir l'exposition aux benzocycloheptènes ?\nY a-t-il des formations pour manipuler ces composés ?\nQuels sont les risques en milieu industriel ?\nDes réglementations existent-elles pour leur usage ?\nComment évaluer les risques d'exposition ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Alendronate#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Benzocycloheptènes",
"description": "Comment traiter une intoxication aux benzocycloheptènes ?\nY a-t-il des antidotes pour ces composés ?\nQuels médicaments peuvent aider en cas d'allergie ?\nLes benzocycloheptènes nécessitent-ils une hospitalisation ?\nComment gérer les effets à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Alendronate#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Benzocycloheptènes",
"description": "Quelles complications peuvent survenir avec ces composés ?\nLes benzocycloheptènes peuvent-ils causer des cancers ?\nY a-t-il des effets sur la reproduction ?\nPeut-on développer des allergies à long terme ?\nLes benzocycloheptènes affectent-ils le système immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Alendronate#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Benzocycloheptènes",
"description": "Qui est le plus à risque d'exposition ?\nL'âge influence-t-il la sensibilité ?\nY a-t-il des prédispositions génétiques ?\nLes antécédents médicaux jouent-ils un rôle ?\nL'environnement de travail influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Alendronate#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les benzocycloheptènes ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par des techniques de spectroscopie et de chromatographie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les benzocycloheptènes ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de toxicité et d'efficacité sont réalisés en laboratoire."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes sont-ils détectables dans le sang ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être détectés par des analyses spécifiques dans des échantillons biologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour ces composés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs biologiques peuvent indiquer l'exposition à ces composés."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour les benzocycloheptènes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie moléculaire peut aider à visualiser leur distribution dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des benzocycloheptènes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent provoquer des nausées, des vertiges ou des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes causent-ils des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs peuvent survenir en cas de toxicité ou d'allergie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des maux de tête ou des troubles de la coordination peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées peuvent survenir en cas de réaction allergique."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes affectent-ils le système respiratoire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition excessive peut entraîner des irritations respiratoires."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition aux benzocycloheptènes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection et suivre les protocoles de sécurité en laboratoire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des formations pour manipuler ces composés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des formations spécifiques sont souvent requises pour les chercheurs."
}
},
{
"@type": "Question",
"name": "Quels sont les risques en milieu industriel ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs peuvent être exposés à des niveaux élevés sans protection adéquate."
}
},
{
"@type": "Question",
"name": "Des réglementations existent-elles pour leur usage ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des réglementations strictes encadrent leur utilisation en laboratoire et en industrie."
}
},
{
"@type": "Question",
"name": "Comment évaluer les risques d'exposition ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des évaluations de risque doivent être effectuées régulièrement dans les environnements de travail."
}
},
{
"@type": "Question",
"name": "Comment traiter une intoxication aux benzocycloheptènes ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'élimination de l'exposition et des soins symptomatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des antidotes pour ces composés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas d'antidote spécifique pour les benzocycloheptènes."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent aider en cas d'allergie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antihistaminiques peuvent être utilisés pour traiter les réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes nécessitent-ils une hospitalisation ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une hospitalisation peut être nécessaire en cas de symptômes graves."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier est recommandé pour surveiller les effets à long terme."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces composés ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des lésions organiques peuvent survenir en cas d'exposition prolongée."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes peuvent-ils causer des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un potentiel cancérigène, mais des recherches supplémentaires sont nécessaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets sur la reproduction ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets néfastes sur la reproduction ont été observés dans certaines études animales."
}
},
{
"@type": "Question",
"name": "Peut-on développer des allergies à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des sensibilisations peuvent se développer avec une exposition répétée."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes affectent-ils le système immunitaire ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition prolongée peut altérer la fonction immunitaire, augmentant les infections."
}
},
{
"@type": "Question",
"name": "Qui est le plus à risque d'exposition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs en laboratoire et en industrie chimique sont les plus exposés."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il la sensibilité ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes et les personnes âgées peuvent être plus sensibles aux effets toxiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines prédispositions génétiques peuvent augmenter la sensibilité aux toxines."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents d'allergies ou de maladies respiratoires augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'environnement de travail influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un environnement de travail mal ventilé augmente le risque d'exposition."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
1 publication dans cette catégorie
Affiliations :
Publications dans "Benzocycloheptènes" :
1 publication dans cette catégorie
Affiliations :
Publications dans "Benzocycloheptènes" :
1 publication dans cette catégorie
Affiliations :
Publications dans "Benzocycloheptènes" :
1 publication dans cette catégorie
Affiliations :
Publications dans "Benzocycloheptènes" :
Buffered and effervescent alendronate (ALN-EFF) increases gastric pH and is reported to decrease the risk of gastrointestinal side effects compared to conventional formulations of alendronate (ALN). T...
Bisphosphonates are commonly prescribed medications to prevent and treat osteoporosis. Although possessing low side effect profiles, the potential for severe topical effects is rare but important. Irr...
Osteoarthritis (OA) is a major cause of pain and disability worldwide. Despite the relatively high burden of the disease, the currently available non-surgical treatment options are directed towards sy...
This multicenter, randomized, double-blinded, placebo-controlled study will evaluate the efficacy and safety of alendronate in early OA. Patients will undergo a 1:1 double-blinded randomization to rec...
This trial will give helpful and high-quality evidence regarding the potential therapeutic role of alendronate sodium vitamin D3, as compared to placebo, in the management of patients with knee OA reg...
This trial was registered on clinicaltrials.gov (registration number: NCT04739592 )....
Bisphosphonates are widely used, notably for osteoporosis treatment. Their common side effects are well known. However, they can trigger less common effects such as orbital inflammation. Here, the cas...
This is a case report at an academic medical center. An orbital magnetic resonance imaging scan, a thoraco-abdominal computed tomography scan and blood sample analyses were performed....
A 66-year-old woman treated by alendronate for her osteoporosis was investigated. She developed an orbital myositis after the first intake. Neurological examination revealed a painful diplopia with de...
This case highlights that alendronate can cause an orbital myositis whose early diagnosis is of major importance because it is a treatable side effect....
Since several additional actions of bone bisphosphonates have been proposed, we studied the effect of the bisphosphonate alendronate (ALN) on the vascular response to environmental stress....
Primary cultures of endothelial cells (EC) and vascular smooth muscle cells (VSMC) exposed to strained conditions were employed for experimental evaluation. After ALN treatment, cell migration, prolif...
In VSMC cultures, ALN counteracted the stimulation of cellular migration elicited by the proinflammatory agent lipopolysaccharide (LPS) or by high levels of calcium and phosphorus (osteogenic medium)....
The findings presented suggest an extra-bone biological action of ALN, which could contribute to the maintenance of vascular homeostasis avoiding cellular damage elicited by environmental stress....
Percutaneous vertebroplasty was the most common strategy for osteoporotic vertebral compression fracture. However, refracture after vertebroplasty also occurred and bone mineral density (BMD) was one ...
To investigate the efficacy of a short-sequential treatment of teriparatide followed by alendronate on prevention of refracture after percutaneous vertebroplasty in osteoporotic patients, and compare ...
From January 2018 to January 2020, we recruited 165 female osteoporosis patients after percutaneous vertebroplasty who were assigned into sequential treatment of teriparatide followed by alendronate g...
The 105 patients were finally included, with 59 in ALN group and 46 in TPTD + ALN group. During 1-year follow-up, the vertebral refracture rate in TPTD + ALN group was much lower than that in ALN grou...
A short-sequential administration of teriparatide followed by alendronate was more effective in elevating the BMD and decreasing the refracture rate at 12-month follow-up, compared to the counterpart ...
Bisphosphonates like alendronate mainly exert their effects on osteoclasts. However, osteoblasts are also affected, but exposed to a much lower concentration...
Primary human osteoblasts were incubated with alendronate (5, 20 and 100 µM) for 1, 3, 7 and 14 days. Proliferation and viability were assessed, and the effects on cellular growth and function were ev...
The viability was not affected by any of the dosages. Exposure to 5 µM alendronate had a neutral effect on osteoblast proliferation, and on secretion of osteogenic and inflammatory markers, while enha...
A concentration of 5 µM alendronate exerted effects on human osteoblasts that may translate to those observed...
The pathogenesis of postmenopausal osteoporosis (PMOP) is mainly determined by the adhesion of osteoclasts to the bone matrix and the involvement of various molecules in bone resorption. The dual regu...
With adequate blood transfusion and iron chelation, thalassemia patients have a longer life expectancy and experience long-term metabolic complications, including osteoporosis, fractures, and bone pai...
We conducted a randomized controlled trial to evaluate the efficacy of alendronate for the treatment of osteoporosis in thalassemia patients. Patients were included if they were males (18-50 years) or...
A total of 51 patients received the study drug, 28 patients were assigned to receive alendronate and 23 patients to receive placebo. At 12 months, patients in the alendronate group had significant imp...
Alendronate 70 mg orally once weekly for 12 months effectively improves BMD at L-spine, reduces serum BTMs, and alleviates back pain in thalassemia patients with osteoporosis. The treatment was well t...
The efficacy of generic teriparatide in improving BMD at lumbar spine in patients with osteoporosis was similar to that of alendronate. It provided a new choice for osteoporosis treatment in Chinese p...
To determine whether the efficacy of generic teriparatide is noninferior to alendronate for Chinese postmenopausal women with osteoporosis....
Eligible patients were randomly assigned (2:1) in a 48-week, open-label design to receive 20 µg sc daily teriparatide or 70 mg oral weekly alendronate. Primary outcome was percentage change in BMD at ...
Three hundred ninety-one and 196 participants were randomly assigned to the teriparatide or alendronate group, of whom 379 and 194 receiving at least one dose of teriparatide and alendronate treatment...
Teriparatide was not inferior to alendronate in increasing BMD at lumbar spine in Chinese postmenopausal women, and they achieved these effects through different mechanisms....
